Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.

Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, Nisato D.

J Cardiovasc Pharmacol. 2005 Feb;45(2):125-35.

PMID:
15654261
2.

Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart.

Guiraudou P, Pucheu SC, Gayraud R, Gautier P, Roccon A, Herbert JM, Nisato D.

Eur J Pharmacol. 2004 Aug 2;496(1-3):119-27.

PMID:
15288583
3.

In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects.

Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, Herbert JM, Nisato D.

J Cardiovasc Pharmacol. 2004 Aug;44(2):244-57.

PMID:
15243307
4.

Effects of differential blockade of the renin-angiotensin system in postinfarcted rats.

Lacour C, Roccon A, Galindo G, Canals F, Hogie M, Segondy D, Briand D, Roque C, Herbert JM, Nisato D.

Fundam Clin Pharmacol. 2004 Jun;18(3):299-307.

PMID:
15147281
5.

Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.

Gautier P, Guillemare E, Marion A, Bertrand JP, Tourneur Y, Nisato D.

J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202.

PMID:
12548079
6.

Shear stress modulates vasopressin-induced renal vasoconstriction in rats.

Loichot C, Krieger JP, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Dec;366(6):555-61. Epub 2002 Oct 2.

PMID:
12444497
7.

Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart.

Pantos C, Mourouzis I, Delbruyère M, Malliopoulou V, Tzeis S, Cokkinos DD, Nikitas N, Carageorgiou H, Varonos D, Cokkinos D, Nisato D.

Eur J Pharmacol. 2002 May 31;444(3):191-6.

PMID:
12063079
8.

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scatton B, Maffrand JP, Le Fur G.

J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.

PMID:
11861823
9.

Renal vascular reactivity to vasopressin in rats with diabetes mellitus.

Loichot C, Anjuère J, Nisato D, De Jong W, Imbs JL, Barthelmebs M.

Eur J Pharmacol. 2001 Nov 23;431(3):321-9.

PMID:
11730725
10.

Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.

Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, Bidouard JP, Janiak P, Schaeffer P, Herbert JM.

J Cardiovasc Pharmacol. 2001 Sep;38(3):395-405.

PMID:
11486244
11.

Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone.

Varró A, Takács J, Németh M, Hála O, Virág L, Iost N, Baláti B, Agoston M, Vereckei A, Pastor G, Delbruyère M, Gautier P, Nisato D, Papp JG.

Br J Pharmacol. 2001 Jul;133(5):625-34.

12.

High concentrations of oxytocin cause vasoconstriction by activating vasopressin V1A receptors in the isolated perfused rat kidney.

Loichot C, Krieger JP, De Jong W, Nisato D, Imbs JL, Barthelmebs M.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):369-75.

PMID:
11330329
13.

Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells.

Guillemare E, Marion A, Nisato D, Gautier P.

J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5.

PMID:
11117382
14.

Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.

Djandjighian L, Planchenault J, Finance O, Pastor G, Gautier P, Nisato D.

J Cardiovasc Pharmacol. 2000 Sep;36(3):376-83.

PMID:
10975596
15.

Effects of angiotensin II AT1-receptor blockade on coronary dynamics, function, and structure in postischemic heart failure in rats.

Gervais M, Fornes P, Richer C, Nisato D, Giudicelli JF.

J Cardiovasc Pharmacol. 2000 Sep;36(3):329-37.

PMID:
10975590
16.

Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure.

Clair MJ, King MK, Goldberg AT, Hendrick JW, Nisato R, Gay DM, Morrison AE, McElmurray JH 3rd, Krombach RS, Bond BR, Cazaubon C, Nisato D, Spinale FG.

J Pharmacol Exp Ther. 2000 Jun;293(3):852-60.

PMID:
10869385
17.

Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats.

Lacour C, Galindo G, Canals F, Segondy D, Cazaubon C, Serradeil-Le Gal C, Roccon A, Nisato D.

Eur J Pharmacol. 2000 Apr 7;394(1):131-8.

PMID:
10771045
18.

Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats.

Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26.

PMID:
10731046
19.

Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition.

Loichot C, Cazaubon C, Grima M, De Jong W, Nisato D, Imbs JL, Barthelmebs M.

Hypertension. 2000 Feb;35(2):602-8.

PMID:
10679504
20.

Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats.

Aimond F, Beck L, Gautier P, Chérif OK, Davy JM, Lorente P, Nisato D, Vassort G.

J Pharmacol Exp Ther. 2000 Jan;292(1):415-24.

PMID:
10604978
21.

Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.

Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF.

Cardiovasc Res. 1999 Jan;41(1):100-8.

PMID:
10325957
22.

[Modulation by nitric oxide of vasopressin induced renal vasoconstriction varies with perfusate viscosity in the isolated rat kidney].

Barthelmebs M, Loichot C, Nisato D, de Jong W, Grima M, Imbs JL.

Arch Mal Coeur Vaiss. 1998 Aug;91(8):1083-6. French.

PMID:
9749170
23.

Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.

Polidori C, Ciccocioppo R, Nisato D, Cazaubon C, Massi M.

Eur J Pharmacol. 1998 Jul 3;352(1):15-21.

PMID:
9718262
24.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G.

J Clin Invest. 1996 Dec 15;98(12):2729-38.

25.

Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney.

Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL.

Eur J Pharmacol. 1996 Oct 31;314(3):325-32.

PMID:
8957254
26.
27.

[Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.

Bax WA, Van der Graaf PH, Stam WB, Bos E, Nisato D, Saxena PR.

Eur J Pharmacol. 1995 Oct 16;285(2):199-202.

PMID:
8566139
28.

Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.

Christophe B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P.

Eur J Pharmacol. 1995 Aug 4;281(2):161-71.

PMID:
7589203
29.

Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development.

Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Giudicelli JF.

J Hypertens. 1995 Jun;13(6):675-82.

PMID:
7594426
30.

Are vasopressin peripheral V1 receptors involved in the development of malignant hypertension and stroke in SHR-SPs?

Vacher E, Richer C, Cazaubon C, Fornes P, Nisato D, Giudicelli JF.

Fundam Clin Pharmacol. 1995;9(5):469-78.

PMID:
8617411
31.

Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.

Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D.

Eur J Pharmacol. 1994 Nov 3;264(3):307-16.

PMID:
7698170
32.

Synthesis and in vitro study of a diglyceride prodrug of a peptide.

Delie F, Couvreur P, Nisato D, Michel JB, Puisieux F, Letourneux Y.

Pharm Res. 1994 Aug;11(8):1082-7.

PMID:
7971705
33.

Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.

Herbert JM, Delisée C, Dol F, Schaeffer P, Cazaubon C, Nisato D, Chatelain P.

Eur J Pharmacol. 1994 Jan 14;251(2-3):143-50.

PMID:
8149971
34.

SR 48692, a non-peptide neurotensin receptor antagonist, blocks the cardiovascular effects elicited by neurotensin in guinea pigs.

Nisato D, Guiraudou P, Barthélémy G, Gully D, Le Fur G.

Life Sci. 1994;54(7):PL95-100.

PMID:
8309346
35.

A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.

Roccon A, Marchionni D, Donat F, Segondy D, Cazaubon C, Nisato D.

Br J Pharmacol. 1994 Jan;111(1):145-50.

36.

Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.

Lacour C, Roccon A, Cazaubon C, Segondy D, Nisato D.

J Hypertens. 1993 Nov;11(11):1187-94.

PMID:
8301099
37.

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al.

J Clin Invest. 1993 Jul;92(1):224-31.

38.

Statine based tripeptides as potent inhibitors of HIV-1 replication.

Fehrentz JA, Chomier B, Bignon E, Venaud S, Chermann JC, Nisato D.

Biochem Biophys Res Commun. 1992 Oct 30;188(2):873-8.

PMID:
1445328
39.

HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity.

Fehrentz JA, Chomier B, Bignon E, Venaud S, Chermann JC, Nisato D.

Biochem Biophys Res Commun. 1992 Oct 30;188(2):865-72.

PMID:
1445327
40.

Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.

Venaud S, Yahi N, Fehrentz JL, Guettari N, Nisato D, Hirsch I, Chermann JC.

Res Virol. 1992 Sep-Oct;143(5):311-9.

PMID:
1480823
41.

A novel class of calcium-entry blockers: the 1[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines.

Gubin J, Lucchetti J, Mahaux J, Nisato D, Rosseels G, Clinet M, Polster P, Chatelain P.

J Med Chem. 1992 Mar 20;35(6):981-8.

PMID:
1552511
42.

A pharmacodynamic study of the renin inhibitor SR 43,845, administered intratracheally in conscious cynomolgus monkeys.

Lacour C, Roccon A, Cazaubon C, Richaud JP, Segondy D, Nisato D.

J Hypertens Suppl. 1991 Dec;9(6):S384-5. No abstract available.

PMID:
1819002
43.

[Hypotensive effect of a new calcium antagonist, SR 33557 in conscious rats].

Lacour C, Canals F, Galindo G, Chatelain P, Nisato D.

Arch Mal Coeur Vaiss. 1990 Jul;83(8):1281-4. French.

PMID:
2124468
44.

[A new method for determination of renin inhibitors].

Cazaubon C, Richaud JP, Nisato D.

Arch Mal Coeur Vaiss. 1990 Jul;83(8):1267-70. French.

PMID:
2124466
45.

Theoretical and experimental conformational analysis of two diastereomeric "Val"-statine derivatives.

Toniolo C, Valle G, Crisma M, Bonora GM, Lelj F, Cristinziano PL, Barone V, Nisato D.

Pept Res. 1990 Jan-Feb;3(1):27-34.

PMID:
2134045
46.

Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca.

Lacour C, Cazaubon C, Roccon A, Segondy D, Wagnon J, Nisato D.

J Hypertens Suppl. 1989 Apr;7(2):S33-5.

PMID:
2666612
47.
48.

Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.

Nisato D, Wagnon J, Callet G, Mettefeu D, Assens JL, Plouzane C, Tonnerre B, Pliska V, Fauchère JL.

J Med Chem. 1987 Dec;30(12):2287-91.

PMID:
3316655
49.

Conformational preferences and self-association modes of two diastereomeric statine derivatives.

Toniolo C, Valle G, Bonora GM, Lelj F, Barone V, Fraternali F, Callet G, Wagnon J, Nisato D.

Int J Pept Protein Res. 1987 Nov;30(5):583-95.

PMID:
3436695
50.

Conformational analysis of pepstatin and related renin inhibitors by 400 MHz 1H n.m.r. spectroscopy.

Roy P, Delepierre M, Wagnon J, Nisato D, Roques BP.

Int J Pept Protein Res. 1987 Jul;30(1):44-53.

PMID:
3312053

Supplemental Content

Loading ...
Support Center